At III content and antithrombin activity in oestrogen-progestogen and progestogen-only treated women

Differential effects of estrogens and progestins on the anticoagulant tissue factor pathway inhibitor in the rat

“…Complete absence of AT is incompatible with life, and individuals with partial deficiencies have an increased incidence of venous thrombosis [28]. Many clinical studies have reported an ∼5-15% reduction in plasma AT in women taking OC and HT [8,14,15,[29][30][31]. In a recent placebo-controlled randomized trial of HT, a significant difference in AT levels was observed in women taking unopposed estradiol versus combined estradiol plus cyclical progestin, suggesting that the progestin may modulate AT plasma levels [13].…”

Effect of estrogen‐progestin hormonal replacement therapy on plasma antithrombin III of postmenopausal women

“…C Acta Obstet Gynecol Scand 77 (1998) recurrent venous thrombosis (3). The association of oral contraceptive drugs and thrombosis has been known for a long time, and estrogen therapy has been considered a risk factor for thromboembolic events, specially in women with other risk factors such as ATIII deficiency (4,5). Estrogens have previously been found to affect ATIII levels and it may be the case in postmenopausal women (6).…”

Response of Serine Antiproteases to Growth Hormone Therapy in Growth Hormone Deficient Children

“…Antithrombin III levels did not change during pregnancy [ 18]. Serum anti thrombin III levels decreased with either estrogen or combined estrogen/progestogen agents [ 19], ai-Antitryp sin does not vary during the menstrual cycle [20], while there is a slight increase in antithrombin III level in mid cycle [21], No information is available on the effect of the menstrual cycle on ai-antichymotrypsin. In our study, only 3 patients had a change in Tanner staging over the course of the study.…”